Related references
Note: Only part of the references are listed.Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)
Jeremie Guedj et al.
HEPATOLOGY (2012)
Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b
J. Vermehren et al.
JOURNAL OF VIRAL HEPATITIS (2012)
HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors
Valeria Cento et al.
PLOS ONE (2012)
Highly Sensitive and Specific Detection of Rare Variants in Mixed Viral Populations from Massively Parallel Sequence Data
Alexander R. Macalalad et al.
PLOS COMPUTATIONAL BIOLOGY (2012)
New HCV therapies on the horizon
J. Vermehren et al.
CLINICAL MICROBIOLOGY AND INFECTION (2011)
Evolving epidemiology of hepatitis C virus
D. Lavanchy
CLINICAL MICROBIOLOGY AND INFECTION (2011)
Protease Inhibitor-Resistant Hepatitis C Virus Mutants With Reduced Fitness From Impaired Production of Infectious Virus
Tetsuro Shimakami et al.
GASTROENTEROLOGY (2011)
Combined X-ray, NMR, and Kinetic Analyses Reveal Uncommon Binding Characteristics of the Hepatitis C Virus NS3-NS4A Protease Inhibitor BI 201335
Christopher T. Lemke et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice
Eiji Ohara et al.
JOURNAL OF HEPATOLOGY (2011)
MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods
Koichiro Tamura et al.
MOLECULAR BIOLOGY AND EVOLUTION (2011)
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bruce R. Bacon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Retreatment of HCV Infection
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ultra-deep sequencing for the analysis of viral populations
Niko Beerenwinkel et al.
CURRENT OPINION IN VIROLOGY (2011)
Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System
Robert A. Fridell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
Oliver Lenz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors
Andrew Bae et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
The resistance mutation R155K in the NS3/4A protease of hepatitis C virus also leads the virus to escape from HLA-A*68-restricted CD8 T cells
Shadi Salloum et al.
ANTIVIRAL RESEARCH (2010)
New NS5B polymerase inhibitors for hepatitis C
Florence Legrand-Abravanel et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
Edward J. Gane et al.
LANCET (2010)
Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034)
Mike Flint et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Development and Characterization of Hepatitis C Virus Genotype 1-7 Cell Culture Systems: Role of CD81 and Scavenger Receptor Class B Type I and Effect of Antiviral Drugs
Judith M. Gottwein et al.
HEPATOLOGY (2009)
Characterization of Resistance to the Protease Inhibitor Boceprevir in Hepatitis C Virus-Infected Patients
Simone Susser et al.
HEPATOLOGY (2009)
Conservation of hepatitis C virus nonstructural protein 3 amino acid sequence in viral isolates during liver transplantation
I. M. V. G. C. Mello et al.
JOURNAL OF VIRAL HEPATITIS (2009)
Hepatitis C protease and polymerase inhibitors in development
Gustine Liu-Young et al.
AIDS PATIENT CARE AND STDS (2008)
Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors
Wengang Yang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Characterization of resistance mutations against HCV ketoamide protease inhibitors
Xiao Tong et al.
ANTIVIRAL RESEARCH (2008)
Resistance mechanisms in HCV: from evolution to intervention
Arthur Y. Kim et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2008)
Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient
Maria Cubero et al.
VIROLOGY (2008)
Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus
Christoph Welsch et al.
GENOME BIOLOGY (2008)
Phenotypic characterization of resistant Val(36) variants of hepatitis C virus NS3-4A serine protease
Yi Zhou et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Clustal W and clustal X version 2.0
M. A. Larkin et al.
BIOINFORMATICS (2007)
Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse
Thomas Vanwolleghem et al.
GASTROENTEROLOGY (2007)
Rapid decline of viral RNA in hepatitis C patients treated with VX-950: A phase Ib, placebo-controlled, randomized study
Hendrik W. Reesink et al.
GASTROENTEROLOGY (2006)
Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase
G Kukolj et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061
C Lin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes
P Simmonds et al.
HEPATOLOGY (2005)
Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose
SJ Hadziyannis et al.
ANNALS OF INTERNAL MEDICINE (2004)
Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061
D Thibeault et al.
JOURNAL OF VIROLOGY (2004)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
MW Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Hepatitis C virus genotyping:: Interrogation of the 5′ untranslated region cannot accurately distinguish genotypes 1a and 1b
ZY Chen et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2002)
Scoring residue conservation
WSJ Valdar
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2002)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
MP Manns et al.
LANCET (2001)
Share Paper
